Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12188/26787
Title: Data Sharing Under the General Data Protection Regulation: Time to Harmonize Law and Research Ethics?
Authors: Vlahou, Antonia
Hallinan, Dara
Apweiler, Rolf
Argiles, Angel
Beige, Joachim
Benigni, Ariela
Bischoff, Rainer
Black, Peter C
Boehm, Franziska
Céraline, Jocelyn
Chrousos, George P
Delles, Christian
Evenepoel, Pieter
Fridolin, Ivo
Glorieux, Griet
van Gool, Alain J
Heidegger, Isabel
Ioannidis, John P A
Jankowski, Joachim
Jankowski, Vera
Jeronimo, Carmen
Kamat, Ashish M
Masereeuw, Rosalinde
Mayer, Gert
Mischak, Harald
Ortiz, Alberto
Remuzzi, Giuseppe
Rossing, Peter
Schanstra, Joost P
Schmitz-Dräger, Bernd J
Spasovski, Goce 
Staessen, Jan A
Stamatialis, Dimitrios
Stenvinkel, Peter
Wanner, Christoph
Williams, Stephen B
Zannad, Faiez
Zoccali, Carmine
Vanholder, Raymond
Issue Date: Apr-2021
Journal: Hypertension (Dallas, Tex. : 1979)
Abstract: The General Data Protection Regulation (GDPR) became binding law in the European Union Member States in 2018, as a step toward harmonizing personal data protection legislation in the European Union. The Regulation governs almost all types of personal data processing, hence, also, those pertaining to biomedical research. The purpose of this article is to highlight the main practical issues related to data and biological sample sharing that biomedical researchers face regularly, and to specify how these are addressed in the context of GDPR, after consulting with ethics/legal experts. We identify areas in which clarifications of the GDPR are needed, particularly those related to consent requirements by study participants. Amendments should target the following: (1) restricting exceptions based on national laws and increasing harmonization, (2) confirming the concept of broad consent, and (3) defining a roadmap for secondary use of data. These changes will be achieved by acknowledged learned societies in the field taking the lead in preparing a document giving guidance for the optimal interpretation of the GDPR, which will be finalized following a period of commenting by a broad multistakeholder audience. In parallel, promoting engagement and education of the public in the relevant issues (such as different consent types or residual risk for re-identification), on both local/national and international levels, is considered critical for advancement. We hope that this article will open this broad discussion involving all major stakeholders, toward optimizing the GDPR and allowing a harmonized transnational research approach.
URI: http://hdl.handle.net/20.500.12188/26787
DOI: 10.1161/HYPERTENSIONAHA.120.16340
Appears in Collections:Faculty of Medicine: Journal Articles

Show full item record

Page view(s)

20
checked on Apr 28, 2024

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.